Search
Your work holds the potential to deliver the next life-changing treatment.
As the world leader in serving science, Thermo Fisher Scientific provides the quality products, services, and support you need to advance your cell and gene therapy from discovery to the clinic. Like you, we believe in the promise provided by these therapies to fundamentally transform the treatment and cure of a range of diseases.
Join us at SCGT Pan Asia Summit 2024 as we share our latest innovations, practical insights and end-to-end manufacturing solutions over:
5 hours of workshop ♦ 6+ Scientific presentations ♦ 3 Poster sessions ♦ 1 Leadership panel discussion
Don’t forget to register, and we look forward to connecting with you in person this July 18-20, 2024!
Find out more about our exciting programmes below.
- Pre-conference workshop
- Scientific programmes
- Booth activities
- Poster sessions
Date: 18 July 2024
Time: 01:00 PM–07:30 PM
Venue: Thermo Fisher Scientific Customer Experience Center (CEC)
Address: 1 Science Park Road, Singapore Science Park II, The Capricorn, #05-07 (West Wing), Singapore 117528
PARALLEL SPECIAL SESSION A
Accelerating Breakthroughs: Current Processes for Cell Therapy Manufacturing and Analysis
| Time (GMT +8) | Programmes | Speakers |
|---|---|---|
| 13:00 – 13:45 | Bus transport from Academia | - |
| 13:45 – 13:55 | Opening address |
Jacqueline Ng Head, Cell & Gene Therapy APJ Thermo Fisher Scientific |
| 13:55 – 14:10 | Introduction to the Gibco™ Cell Therapy Systems™ |
Ryan Lim, PhD Business development manager IPAC Thermo Fisher Scientific |
| 14:10 – 14:30 | Hear from developers: Experiences in cell and gene therapy manufacturing in Asia |
Shin Kawamata, MD, PhD CEO, Cyto-Facto Inc. Project Professor, Graduate School of Science, Technology and Innovation, Kobe University Penny Tan, PhD Global head, Auxi Therapeutics Sdn Bhd |
| 14:30 – 17:05 |
Station rotations*
|
Thermo Fisher Scientific Cell & Gene Therapy subject matter experts and application specialists:
|
| 17:05 – 19:30 | Networking and awards dinner | - |
Date: 19-20 July 2024
Time: 08:00 AM - 06:30 PM
Venue: Academia, 20 College Road, Singapore 169856
- Conference Day 1
- Conference Day 2
DAY 1 LUNCH SYMPOSIUM
Regional Spotlight: Clinical Development and Translation Of Cell-based Therapies
| Time (GMT +8) | Speakers and topics |
| 12:30 – 13:00 | 
Stem cell therapy for brain diseases Masahito Kawabori, MD, PhD Associate Professor, Department of Neurosurgery, Graduate School of Medicine, Hokkaido University, Japan |
| 13:00 – 13:30 | 
Automated closed-system processing of blood products by counterflow centrifugation for advanced cell therapy manufacture
Leon Brownrigg, PhD Senior Medical Scientist, Cell and Tissue Therapies WA (CTTWA), Royal Perth Hospital, Australia |
DAY 1 PANEL ROUNDTABLE DISCUSSION
Future-proof Your Development: Considerations around Raw Material Qualification and GMP Manufacturing
| Time (GMT +8) | Speakers and topics |
| 15:00 – 16:00 | 
Chairperson: Amy Butler, PhD. Division President of Biosciences, Thermo Fisher Scientific. |
Panelist:
Zlatibor Velickovic, PhD Regional Vice-President Elect (ANZ), International Society for Cell & Gene Therapy, Australia |
|
Panelist:
Kasey Kime Director, Regulatory Affairs – Life Sciences, Thermo Fisher Scientific |
|
Panelist:
Ji-Hyeon Ju, MD, PhD CEO, YiPSCELL Inc., South Korea |
|
Panelist:
Pawan Gupta, MBBS, MD, DNB, PhD Regional Vice-President Elect (Asia), International Society for Cell & Gene Therapy, India |
|
|
Panelist:
Dr. Kellathur Nadathur Srinivasan Regional Regulatory Policy Lead APAC, Pharma Technical Regulatory, Roche Singapore |
DAY 2 PARALLEL SESSION 4
Sponsored Oral Presentation
| Time (GMT +8) | Speakers and topics |
| 13:30 – 14:00 | 
Let’s talk scale: a new dimension to GMP-compliant iPSC manufacturing Soong Poh Loong, PhD Field Application Scientist, Thermo Fisher Scientific |
DAY 2 PARALLEL SESSION 6B
Regional Development in Cell Therapy, Clinical Adoption and Commercialisation of Cell Therapies in Asia
| Time (GMT +8) | Speakers and topics |
| 17:00 – 18:00 |
Cell and gene therapy development experience of iPSC-derived injectable spheroids in South Korea Ji-Hyeon Ju, MD, PhD CEO, YiPSCELL Inc., South Korea |
Process development for NK cells differentiation from induced pluripotent stem cells
Rafal Krol, MD, PhD Principal Investigator, Research and Development Center, CiRA Foundation Japan |
|
|
Pending topic
Alok Srivastava, MD, FRACP, FRCPA, FRCP Senior Professor, Department of Haematology Head, Centre for Stem Cell Research Christian Medical College Vellore, India |
Date: 19-20 July 2024
Time: 08:00 AM - 06:30 PM
Venue: Academia, 20 College Road, Singapore 169856
BOOTH ACTIVITIES
Coming soon!
CTS StemScale PSC Suspension Medium new!
A new dimension to PSC culture for cell therapy
Learn more ›
Closed manufacturing systems and single-use technologies
Explore our virtual lab ›
Image courtesy of SCGT Pan Asia Summit 2024 organizers
Date: 19 July 2024
Time: 05:30 PM – 06:30 PM
Venue: Academia, 20 College Road, Singapore 169856
POSTER PRESENTATION
| Posters # | Topics |
|---|---|
 # |
Non-viral genome editing in Hematopoietic Stem Cells (HSCs) for cell-therapy applications - from discovery to manufacturing Abstract Optimizing electroporation conditions with the right parameters is crucial to ensure efficient and successful transfection of cells, maximizing the desired outcomes of gene editing or other applications. The Invitrogen™ Neon™ NxT Electroporation System scalability to the large-scale Gibco CTS™ Xenon™ electroporation system offers researchers a versatile platform for small-scale optimization, enabling a smooth transition from initial experiments to large-scale applications The cell processing and delivery instruments together with gene editing reagents and optimized gene delivery protocols developed through this work offers a robust solution for efficient and precise engineering of hematopoietic stem cells (HSCs) in various research and therapeutic applications. |
 # |
Scalable solutions for expansion of non-virally generated CAR T cells Abstract Biomanufacturers rely on bioreactors with closed designs to grow genetically modified immune cells for cell therapy development, as they offer reduced risk of contamination. Generally, they use static bioreactors or those that agitate cells through rocking or stirring. In a previous application note, it was demonstrated that expansion of unedited T cells using automated stirred-tank (STR) bioreactors was improved compared to static bioreactors. This study aims to investigate the impact of expanding genetically edited T cells in a stirred tank bioreactor compared to a static bioreactor. |
 # |
Feasibility of Wash and Formulation of Mesenchymal Stem Cells in Low-volume for Intra-tumoral Delivery Using Closed Counterflow Centrifugation Abstract Purpose: Pre-clinical development of a GMP-compliant, closed process, to wash and formulate modified human Mesenchymal Stem Cells (hMSCs) in low harvest volumes for intratumoral administration, with specific interest for recurrent Glioblastoma (GBM) treatment. Methods: Human MSCs are expanded and engineered with a GFP expressing construct using NUS’s proprietary non-viral gene delivery method in 5-chamber CellStack, generating 0.5 billion engineered hMSCs. Prior to cryopreservation, the transfection efficiency and cell viability were determined by Flow Cytometry and NC-3000 nucelocounter, respectively. To remove DMSO from the cell product, CTS™ Rotea™ counterflow centrifuge system was evaluated. A 10-minute cell-wash and harvest protocol was applied. Excipient-grade Hartmann’s solution was used as a wash and the hypothermosol was used as formulation buffer. To assess cell quality and functionality, hMSCs were stored at 4degC for up to 4 hours. Results: Cell harvest volumes ranged from 2.9mL – 3.5mL is possible. At various number of cell input (80-220 x 106), viable cell recovery was >60%. At cell viability >80%, the % of transfected cells, phenotypic characteristic and the anti-cancer potency of the engineered MSCs remain unchanged. |